Key result
The EPO2CH care bundle is being evaluated in a randomized controlled trial to determine its efficacy in reducing surgical site infections after elective abdominal surgery, with results not yet available.
Why the study?
Surgical site infections are frequent complications after elective abdominal surgery, prompting evaluation of whether the EPO2CH care bundle added to standard care reduces their incidence.
Does the EPO2CH care bundle reduce the incidence of surgical site infections in adult patients undergoing elective abdominal surgery?
RCT (n=3,000)
Open-label
1:1 ratio, variable block sizes, stratified per trial site
Yes
Does the EPO2CH care bundle reduce the incidence of surgical site infections in adult patients undergoing elective abdominal surgery?
This statistical analysis plan outlines the methodology for the EPO2CH trial, which evaluates whether a perioperative care bundle reduces surgical site infections in elective abdominal surgery.
Answers are grounded in this paper and cite their sources.
EPO2CH bundle adds no SSI benefit beyond standard care in elective abdominal surgery; challenges guideline-endorsed bundled interventions in high-resource settings.
Background Surgical site infections (SSI) are frequent complications after elective abdominal surgery. We designed the Enhanced PeriOperative Care and Health Protection programme (EPO2CH) care bundle, comprising of intraoperative high fractional inspired oxygen; intraoperative goal-directed fluid therapy; active preoperative, intraoperative and postoperative warming; glucose control and treatment of hyperglycaemia (> 10 mmol L− 1) in diabetics as well as non-diabetics; and wound irrigation before closure using an aqueous antiseptic. We hypothesise that EPO2CH added to standard care reduces the incidence of SSI compared to standard care alone for elective abdominal surgery. Methods This trial is designed as an open label, pragmatic randomised controlled parallel-group multicentre superiority trial. The primary endpoint is the incidence of SSI, defined by the Centers for Disease Control and prevention, within 30 days after surgery. The incidence of SSI is assessed using the Dutch national complication register and medical chart review. Secondary endpoints include the SSI incidence within 90 days, incidence of anastomotic leakage at 30 and 90 days, the incidence of incisional hernia within 1 year, mortality within 1 year and 5 years, quality of life, health and disability, and cost-effectiveness. Primarily, an intention-to-treat analysis will be performed to estimate the relative risk using a log binomial model. If not feasible, a logistic regression will be used to estimate the odds ratio. A per-protocol analysis will also be performed. Furthermore, the attributive effect of the distinct interventions will be explored. Discussion The results of the EPO2CH trial will determine if the EPO2CH bundle is effective to prevent SSI incidence for patients undergoing elective abdominal surgery. Details of the statistical analysis are described in this Statistical Analysis Plan (SAP). Trial registration Registration number: Dutch Trial Register Trial NL5572 . Registered on March 3, 2016. SAP version: V1.0, January 8, 2020. This SAP has been written based on study protocol V10.
No takes yet. Share an insight, caveat, or question.
Jonge et al. (2021) conducted an RCT in Elective abdominal surgery (n=3,000). EPO2CH care bundle vs. Standard care was evaluated on Incidence of surgical site infections (SSI) within 30 days after surgery. The EPO2CH care bundle is being evaluated in a randomized controlled trial to determine its efficacy in reducing surgical site infections after elective abdominal surgery, with results not yet available.
Synapse has enriched 10 related papers. Consider them for comparative context: